

## EFNS/PNS PDN GUIDELINES

# European Federation of Neurological Societies/Peripheral Nerve Society Guideline\* on management of paraproteinemic demyelinating neuropathies. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society

Joint Task Force of the EFNS and the PNS†

---

**Abstract** Background: Paraprotein-associated neuropathies have heterogeneous clinical, neurophysiological, neuropathological, and hematological features. Objectives: The aim of this guideline was to prepare evidence-based and consensus guidelines on the clinical management of patients with both a demyelinating neuropathy and a paraprotein [paraproteinemic demyelinating neuropathy (PDN)]. Methods: Disease experts and a representative of patients considered references retrieved from MEDLINE and the Cochrane Library and prepared statements that were agreed in an iterative fashion. Recommendations: In the absence of adequate data, evidence-based recommendations were not possible, but the Task Force agreed on the following good practice points: (1) patients with PDN should be investigated for a malignant plasma cell dyscrasia; (2) the paraprotein is more likely to be causing the neuropathy if the paraprotein is immunoglobulin M (IgM), antibodies are present in serum or on biopsy, or the clinical phenotype is chronic distal sensory neuropathy; (3) patients with IgM PDN usually have predominantly distal and sensory impairment, with prolonged distal motor latencies, and often anti-myelin-associated glycoprotein antibodies; (4) IgM PDN sometimes responds to immunotherapies. Their potential benefit should be balanced against their possible side effects and the usually slow disease progression; (5) IgG and IgA PDN may be indistinguishable from chronic inflammatory demyelinating polyradiculoneuropathy clinically, electrophysiologically, and in response to treatment; and (6) for POEMS syndrome, local irradiation or resection of an isolated plasmacytoma, or melphalan with or without corticosteroids, should be considered, with hemato-oncology advice.

**Key words:** definition, diagnosis, guidelines, paraproteinemic demyelinating neuropathy, treatment

---

---

Address correspondence to: Dr. Robert Hadden, Department of Neurology, King's College Hospital, Denmark Hill, London SE5 9RS, UK. E-mail: rob.hadden@doctors.org.uk

\*Anticipated date for updating this guideline: Not later than October 2008.

†Membership of Task Force: Robert D. Hadden, UK; Eduardo Nobile-Orazio, Italy; Claudia Sommer, Germany; Angelika Hahn, Canada; Isabel Illa, Spain; Enrica Morra, Italy; John D. Pollard, Australia; Richard A.C. Hughes (Chair), UK; Pierre Bouche, France; David R. Cornblath, USA; Eileen Evers, UK; Carol L. Koski, USA; Jean-Marc Léger, France; Peter Van den Bergh, Belgium; Pieter A. van Doorn, Netherlands; Ivo N. van Schaik, Netherlands.

## Objectives

The aim of this guideline was to construct clinically useful guidelines for the diagnosis, investigation, and treatment of patients with both a demyelinating neuropathy and a paraprotein [paraproteinemic demyelinating neuropathy (PDN)], based on the available evidence and, where evidence was not available, consensus.

## Background

The neuropathies associated with paraproteins (monoclonal gammopathy and monoclonal immunoglobulin) are difficult to classify because of heterogeneity in the clinical and electrophysiological features of the neuropathy, the class, immunoreactivity, and pathogenicity of the paraprotein, and the malignancy of the underlying plasma cell dyscrasia (Yeung *et al.*, 1991; Latov, 1995; Ropper and Gorson, 1998). In the absence of an agreed diagnostic classification, it is not yet possible to provide specific diagnostic criteria, and treatment trials are more difficult to interpret.

Many patients with PDN have a neuropathy that is indistinguishable from chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), and there is no consensus on whether these should be considered the same or different diseases. We aim to be as inclusive as possible but have chosen to concentrate in this guideline on demyelinating neuropathies. Axonal neuropathies with a paraprotein are not part of the scope of these guidelines but are mentioned briefly in section *Other neuropathy syndromes associated with paraproteinemia*. As both paraproteins and neuropathies are common, it may be uncertain whether the paraprotein is causing the neuropathy or is coincidental.

## Search Strategy

We searched MEDLINE from 1980 onwards on July 24, 2004, for articles on PDN and 'diagnosis' or 'treatment' or 'guideline' and used the personal databases of Task Force members. We also searched the Cochrane Library in September 2004.

## Methods for Reaching Consensus

Pairs of Task Force members prepared draft statements about classification, investigation, and treatment which were considered at a meeting in September 2004. Evidence was classified as classes I–IV, and recommendations were classified as levels A–C (Brainin *et al.*, 2004). When only class IV evidence was available but consensus could be reached, the Task Force has offered advice as good practice points. The statements were collated into a single document

that was revised iteratively until consensus was reached.

## Results

Any diagnostic classification of PDN must take account of the dimensions of clinical phenotype, immunoglobulin (Ig) class, malignant plasma cell dyscrasia, presence of antibodies to myelin-associated glycoprotein (MAG), electrophysiological phenotype, and causal relationship of the paraprotein to the neuropathy (Table 1). There is no consensus in the literature on which should take precedence in classification. Here, we distinguish IgM from IgG and IgA PDNs because IgM PDN tends to have a typical clinical phenotype, pathogenic antibodies, a causal relationship between paraprotein and neuropathy, and the evidence about treatment is different. Nevertheless, there is a significant overlap between the clinical and electrophysiological features of the neuropathy with different types of paraprotein.

The website gives a table summarizing some of the published evidence on investigation of PDN ([http://pns.ucsd.edu/PDN\\_Guidelines\\_Supplement.pdf](http://pns.ucsd.edu/PDN_Guidelines_Supplement.pdf)).

## Investigation and classification of the paraproteins

### Background

Although some paraproteins are detected by standard serum protein electrophoresis (SPEP), both serum immunoelectrophoresis (SIEP) and serum immunofixation electrophoresis (SIFE) are more sensitive techniques which detect lower paraprotein concentrations (Vrethem *et al.*, 1993; Keren, 1999). Heavy- (IgM, IgG, or IgA) and light-chain (kappa or lambda) class should be identified. A paraprotein indicates an underlying disease of plasma cells in bone marrow, which may be malignant (and may itself require treatment) or a monoclonal gammopathy of uncertain significance (MGUS) (Table 2) (*International Myeloma Working Group*, 2003). For detection of myeloma bone lesions, X-ray skeletal survey has similar sensitivity to Tc99m sesta-MIBI (2-methoxy-isobutyl-isonitrile), and both are superior to conventional radionuclide scintigraphy (Ludwig *et al.*, 1982; Balleari *et al.*, 2001; Alper *et al.*, 2003), although these studies did

**Table 1.** Dimensions in the classification of paraproteinemic demyelinating neuropathy.

- 
1. Clinical phenotype
  2. Immunoglobulin class
  3. Monoclonal gammopathy of undetermined significance or malignant plasma cell dyscrasia
  4. Presence of antibodies to myelin-associated glycoprotein
  5. Electrophysiology
  6. Likelihood that paraprotein is causing the neuropathy
-

**Table 2.** Classification of hematological conditions with a paraprotein.

---

(1) Malignant monoclonal gammopathies
(a) Multiple myeloma [overt, asymptomatic (smouldering), non-secretory, or osteosclerotic]
(b) Plasmacytoma (solitary, extramedullary, and multiple solitary)
(c) Malignant lymphoproliferative disease:
(i) Waldenström's macroglobulinemia
(ii) Malignant lymphoma
(iii) Chronic lymphocytic leukemia
(d) Heavy-chain disease
(e) Primary amyloidosis (with or without myeloma)
(2) Monoclonal gammopathy of undetermined significance

---

not distinguish osteolytic from osteosclerotic myeloma.

*Recommended investigations*

Table 3 suggests investigations to be considered in all patients with a paraprotein. SIFE should be performed in all cases of known paraprotein to define the heavy- and light-chain types, in all acquired demyelinating neuropathies, and if a paraprotein is suspected but not detected by standard SPEP.

*Definition of MGUS*

The definition of MGUS for IgM is different from that for IgG and IgA (Table 4). Patients with IgM MGUS have alternatively been classified as 'IgM-related disorders' if they have clinical features attributable to the paraprotein (such as neuropathy), or as 'asymptomatic IgM monoclonal gammopathy' (Owen, 2003).

Good prognostic features suggesting a low risk of malignant transformation are:

- 1 IgM MGUS: normal full blood count (in particular, hemoglobin >12.5 g/dL and lymphocytes <4 × 10<sup>9</sup>/L), absence (or only a small amount) of Bence-Jones protein in the urine, erythrocyte sedimentation rate (ESR) <40 mm/h, and monoclonal protein <30 g/L (Morra et al., 2004);

- 2 IgG/IgA MGUS: absence (or only small amount) of Bence-Jones protein in the urine, no reduction of polyclonal serum immunoglobulin concentrations, ESR <40 mm/h, <5% bone marrow plasma cell infiltration, and monoclonal protein <20 g/L (Gregersen et al., 2001; Cesana et al., 2002).

**Typical syndromes of PDN**

The most common types of PDN are those with demyelinating neuropathy and MGUS without non-neurological symptoms. The neuropathy is defined as demyelinating if it satisfies electrophysiological criteria for CIDP (Hughes et al., 2005). If there are subtle features of demyelination not meeting these criteria, further investigations should be considered to confirm evidence of immune-mediated demyelination (see section *Cerebrospinal fluid and nerve biopsy*).

*IgM PDN*

Clinical phenotype

Most patients with IgM PDN have the 'distal acquired demyelinating symmetrical' (DADS) clinical phenotype of predominantly distal, chronic (duration over 6 months), slowly progressive, symmetric, predominantly sensory impairment, with ataxia and relatively mild or no weakness, and often tremor (class IV evidence) (Yeung et al., 1991; Maisonobe et al.,

**Table 3.** Investigation of a paraprotein.

The following should be considered in all patients with a paraprotein:

1. Serum immunofixation electrophoresis
  2. Physical examination for peripheral lymphadenopathy, hepatosplenomegaly, macroglossia, and signs of POEMS syndrome (see section *Other neuropathy syndromes associated with paraproteinemia*)
  3. Full blood count, renal and liver function, calcium, phosphate, erythrocyte sedimentation rate, C-reactive protein, uric acid, β<sub>2</sub>-microglobulin, lactate dehydrogenase, rheumatoid factor, serum cryoglobulins
  4. Total immunoglobulin G (IgG), IgA, IgM concentrations
  5. Random urine collection for the detection of Bence-Jones protein (free light chains), and, if positive, 24 h urine collection for protein quantification
  6. Radiographic X-ray skeletal survey, including skull, pelvis, spine, ribs, long bones (shoulder to wrist, and hip to ankle), to look for lytic or sclerotic lesions. If this is negative, then a Tc99m sesta-MIBI (2-methoxy-isobutyl-isonitrile) scan if high degree of suspicion of myeloma (IgA lambda and IgG lambda paraproteins are more frequently associated with osteosclerotic myeloma)
  7. Ultrasound or computed tomography of abdomen and chest (to detect lymphadenopathy, hepatosplenomegaly)
  8. Consultation with a hematologist and bone marrow examination (morphology, immunophenotype and biopsy)
-

**Table 4.** Definition of monoclonal gammopathy of undetermined significance (MGUS).

- 
- (1) IgM-MGUS is defined by the presence of all of the following:
    - (a) No lymphoplasmacytic infiltration on bone marrow biopsy, or equivocal infiltration with negative phenotypic studies
    - (b) No signs or symptoms suggesting tumor infiltration (e.g., constitutional symptoms, hyperviscosity syndrome, organomegaly)
    - (c) No evolution to malignant lymphoproliferative disease requiring treatment within 12 months from first detection of paraprotein
  - (2) IgG or IgA-MGUS is defined by the presence of all of the following:
    - (a) Monoclonal component  $\leq 30$  g/L
    - (b) Bence-Jones proteinuria  $\leq 1$  g/24 h
    - (c) No lytic lesions in bone
    - (d) No anemia, hypercalcemia, or chronic renal insufficiency
    - (e) Bone marrow plasma cell infiltration  $< 10\%$
    - (f) No evolution to myeloma or other lymphoproliferative disease within 12 months after first detection of paraprotein
- 

1996; Chassande et al., 1998; Simovic et al., 1998; Capasso et al., 2002; Magy et al., 2003). The DADS phenotype is most strongly associated with IgM anti-MAG antibodies, and some patients have more prominent ataxia with impairment predominantly of vibration and joint position sense. However, the clinical features do not correlate exactly with the paraprotein type: a minority of patients with IgM PDN have proximal weakness with the phenotype more typical of IgG/IgA PDN, and some DADS patients do not have a paraprotein so that they are classified as a variant of CIDP (Katz et al., 2000).

#### Electrophysiology

Patients with the DADS clinical phenotype usually meet the definite electrophysiological criteria proposed for CIDP. They may also have additional specific electrophysiological features indicating uniform symmetrical and predominantly distal reduced conduction velocity, usually without conduction block (Table 5, adapted from Kaku et al., 1994; Notermans et al., 2000; Capasso et al., 2002).

#### Antibodies to MAG and other neural antigens

Almost 50% of patients with IgM PDN have high titers of anti-MAG IgM antibodies (Nobile-Orazio et al., 1994), more commonly associated with kappa than lambda light chains, and this is the best defined syndrome of PDN (Van den Berg et al., 1996). Testing of antibodies to neural antigens should be considered in patients with IgM PDN (Table 6).

#### IgG or IgA PDN

Patients with IgG or IgA PDN usually have both proximal and distal weaknesses, with motor and

sensory impairment, indistinguishable clinically and electrophysiologically from typical CIDP. They usually have more rapid progression than DADS (Simovic et al., 1998; Di Troia et al., 1999; Magy et al., 2003). However, a minority of patients with IgG or IgA PDN have the DADS clinical phenotype and associated electrophysiological features. In patients with IgG or IgA paraprotein, no specific antibody has been consistently associated with demyelinating neuropathy, and therefore, there is no need for antibody testing.

#### Other neuropathy syndromes associated with paraproteinemia

This section briefly mentions other types of neuropathies associated with a paraprotein, including those with hematological malignancy, systemic symptoms, or axonal electrophysiology, although these are not part of the main guidelines and not discussed in detail.

#### POEMS

POEMS (polyneuropathy, organomegaly, endocrinopathy, M band, and skin changes) syndrome usually has an underlying osteosclerotic myeloma, with IgA or IgG lambda paraprotein but is sometimes associated with Castleman's disease. POEMS neuropathy has clinical features similar to those of CIDP. Many patients are initially thought to have CIDP or ordinary PDN, until POEMS is suggested by the presence of systemic features such as sclerotic bone lesions, hepatosplenomegaly, lymphadenopathy, endocrinopathy, papilledema, skin

**Table 5.** Electrophysiological features associated with the distal acquired demyelinating symmetric (DADS) clinical phenotype.

- 
- 1. Uniform symmetrical reduction of conduction velocities; more severe sensory than motor involvement
  - 2. Disproportionately prolonged distal motor latency (DML). This may be quantified by low terminal latency index (TLI). TLI is defined as distal velocity/intermediate velocity = distal distance/(motor conduction velocity  $\times$  DML).  $TLI \leq 0.25$  is suggestive of the DADS phenotype
  - 3. Severe involvement of peroneal nerves
  - 4. Absent sural potential (i.e., less likely to have the 'abnormal median, normal sural' sensory action potential pattern)
  - 5. Partial motor conduction block (i.e., proximal/distal compound muscle action potential amplitude ratio  $< 0.5$ ) is very rare
-

**Table 6.** Antibodies against neural antigens in patients with immunoglobulin M (IgM) paraproteinemic demyelinating neuropathy (PDN).

(1) In patients with IgM PDN, testing for antibodies to myelin-associated glycoprotein (MAG) should be considered. These antibodies may be considered to be:

- (a) Definite if Western blot against human MAG positive at a titer of 1/6,400 or more
- (b) Probable if enzyme-linked immunosorbent assay (ELISA) against sulfated glucuronyl paragloboside (SGPG) or human MAG positive at high titer (usually 1/6,400 or more, but depends on the laboratory and system used)
- (c) Possible if presence of complement-fixing antibodies to peripheral nerve homogenate, or IgM binding to myelin detected by indirect immunohistochemistry or immunofluorescence of nerve sections (these methods are not specific and may also be positive in patients with high-titer anti-sulfatide IgM), or lower titers by (a) or (b)

(2) In patients with IgM PDN without anti-MAG antibodies, testing for IgM antibodies against other neural antigens, including gangliosides GQ1b, GM1, GD1a and GD1b, SGPG, and sulfatide, may be considered. The presence of these antibodies increases the probability of, but does not prove, a pathogenetic link between the paraprotein and the neuropathy. Their diagnostic relevance is not defined

(3) In suspected CANOMAD, testing for anti-ganglioside antibodies should be considered (preferably by thin-layer chromatography, but anti-GQ1b ELISA may be adequate)

changes (hypertrichosis, hyperpigmentation, diffuse skin thickening, finger clubbing, dermal hemangiomas, and white nail beds), and edema (*Dispenzieri et al., 2003*).

Electrophysiology often shows a mixed demyelinating and axonal picture (*Kelly, 1983*). Features that help distinguish POEMS from CIDP include reduced motor nerve conduction velocities more marked in intermediate than in distal nerve segments (terminal latency index 0.35–0.5, the opposite of the DADS phenotype), rarity of conduction block, and compound muscle action potential amplitudes smaller in lower than in upper limbs (*Sung et al., 2002*).

There is no specific diagnostic test for POEMS, but if it is suspected, the following investigations should be considered: endocrine blood tests (thyroid, follicle-stimulating hormone, luteinizing hormone, glucose, prolactin, and morning cortisol); ultrasound or computed tomography of abdomen and chest (organomegaly and lymphadenopathy); skin biopsy [may show distinctive glomeruloid hemangiomas in the dermis (*Chan et al., 1990*)]; serum vascular endothelial growth factor (*Watanabe et al., 1998*); and nerve biopsy [may show uncompact myelin lamellae (*Vital et al., 2003*)].

#### *Waldenström's macroglobulinemia*

Waldenström's macroglobulinemia is defined by the presence of an IgM (usually kappa) paraprotein (irrespective of concentration) and a bone marrow biopsy showing infiltration by lymphoplasmacytic lymphoma with a predominantly intertrabecular pattern, supported by appropriate immunophenotypic studies (*Owen, 2003*). The associated neuropathy is clinically heterogeneous, but sometimes associated with anti-MAG reactivity and clinical features of IgM anti-MAG neuropathy (*Baldini et al., 1994*).

#### *CANOMAD*

The syndrome of chronic ataxic neuropathy with ophthalmoplegia, IgM monoclonal gammopathy, cold agglutinins, and disialoganglioside (IgM anti-GD1b/GQ1b) antibodies (CANOMAD) is a rare neuropathy similar to chronic Fisher syndrome, with mixed demyelinating and axonal electrophysiology (*Willison et al., 2001*).

#### *Other neuropathies with a paraprotein*

Axonal neuropathy is often present in patients with MGUS, but the pathogenesis and causal relationship vary, and it will not be considered further in these guidelines. A few patients with cryoglobulinemia (*Vital et al., 2000*) or primary (AL) amyloidosis (*Vital et al., 2004*) have demyelinating neuropathy, although far more have axonal neuropathy. AL-amyloidosis should be suspected in the presence of prominent neuropathic pain or dysautonomia and may be demonstrated by biopsy of rectum, bone marrow, kidney or nerve, or fat aspirate.

In patients with lytic multiple myeloma (usually associated with IgA or IgG kappa or lambda paraprotein), neuropathy may be caused by heterogeneous mechanisms, including amyloidosis, metabolic and toxic insults, and cord or root compression due to vertebral collapse from lytic lesions (*Kelly et al., 1981*). Subacute weakness similar to Guillain-Barré syndrome may be caused by extensive infiltration of nerves or roots by lymphoma or leukemia (*Diaz-Arrastia et al., 1992*).

#### **Is the paraprotein causing the neuropathy?**

A causal relationship is more likely with an IgM than an IgG or IgA paraprotein. Our Task Force has classified CIDP with a paraprotein separately from CIDP without a paraprotein, but there is still no consensus among experts on whether IgG or IgA PDN

may merely be CIDP with a coincidental paraprotein. Malignant paraproteins may also cause a neuropathy, but the mechanism is incompletely understood. The only published criteria of causality were in a study in which all patients had the DADS phenotype, demyelinating physiology, and MGUS (IgM or IgG) (Notermans *et al.*, 2000). We extensively modified these criteria and propose factors that suggest whether the paraprotein is likely to be causing the neuropathy (Table 7).

### Cerebrospinal fluid and nerve biopsy

Cerebrospinal fluid (CSF) examination and nerve biopsy may be helpful in selected circumstances (Table 8, good practice points) but are not usually necessary if there is clearly demyelinating physiology with MGUS. The CSF protein is elevated in 75–86% of patients with PDN (Notermans *et al.*, 2000; Capasso *et al.*, 2002). The presence of widely spaced myelin outer lamellae on electron microscopy is highly sensitive and specific for anti-MAG neuropathy. Immunoglobulin deposits may be identified on nerve structures (Vallat *et al.*, 2000; Mehndiratta *et al.*, 2004).

### Treatment of PDN

#### Monitoring of hematological disease

Patients with MGUS or asymptomatic Waldenström's macroglobulinemia do not need treatment, unless required specifically because of neuropathy or other IgM-related conditions, according to a consensus panel guideline (Kyle *et al.*, 2003). Whether they have a neuropathy or not, they should have regular hematological evaluation for early detection of malignant transformation, which occurs at approximately 1.3% per year. The following should be measured: paraprotein concentration, Bence-Jones protein in the urine, serum immunoglobulin concentrations, ESR, creatinine,

calcium,  $\beta$ 2-microglobulin, and full blood count, at a frequency of once a year for MGUS, every 6 months for asymptomatic Waldenström's macroglobulinemia, or every 3 months if there is a higher risk of malignant transformation (Gregersen *et al.*, 2001; Cesana *et al.*, 2002; Morra *et al.*, 2004) (good practice point).

#### IgM PDN

A recent Cochrane review of anti-MAG paraproteinemic neuropathy concluded that there is so far inadequate reliable evidence to recommend any particular immunotherapy (Lunn and Nobile-Orazio, 2003). The same conclusion may be extended to IgM paraprotein-associated neuropathy without anti-MAG antibodies. Based on evidence regarding the pathogenicity of anti-MAG antibodies, therapy has been directed at reducing circulating IgM or anti-MAG antibodies by removal [plasma exchange (PE)], inhibition [intravenous immunoglobulin (IVIg)], or reduction of synthesis (corticosteroids, immunosuppressive agents, cytotoxic agents, or interferon- $\alpha$ ). Only five controlled studies on a total of 97 patients have been performed (Lunn and Nobile-Orazio, 2003).

#### PE

In a review of uncontrolled studies or case reports (Nobile-Orazio *et al.*, 2000), PE was temporarily effective in approximately half of the patients both alone and in combination with other therapies (class IV evidence). However, this was not confirmed in two controlled studies. In one, a randomized comparative open trial on 44 patients with neuropathy associated with IgM monoclonal gammopathy, 33 of whom had anti-MAG IgM, showed that the combination of PE with chlorambucil was no more effective than chlorambucil alone (Oksenhendler *et al.*, 1995) (class III). In a double-blind sham-controlled trial on 39 patients with

**Table 7.** Causal relationship between paraprotein and demyelinating neuropathy.

- 
- (1) Highly probable if immunoglobulin M (IgM) paraprotein [monoclonal gammopathy of uncertain significance (MGUS) or Waldenström's] and:
- High titers of anti-myelin-associated glycoprotein (anti-MAG) or anti-GQ1b antibodies, or
  - Nerve biopsy shows IgM or complement deposits on myelin, or widely spaced myelin on electron microscopy
- (2) Probable if either:
- IgM paraprotein (MGUS or Waldenström's) with high titers of IgM antibodies to other neural antigens (GM1, GD1a, GD1b, GM2, sulfatide, etc.), and slowly progressive predominantly distal symmetrical sensory neuropathy, or
  - IgG or IgA paraprotein and nerve biopsy evidence (as in 1b but with IgG or IgA deposits)
- (3) Less likely when any of the following are present in a patient with MGUS and without anti-MAG antibodies (diagnosis may be described as 'chronic inflammatory demyelinating polyradiculoneuropathy with coincidental paraprotein'):
- Time to peak of neuropathy <6 months
  - Relapsing/remitting or monophasic course
  - Cranial nerves involved (except CANOMAD)
  - Asymmetry
  - History of preceding infection
  - Abnormal median with normal sural sensory action potential
  - IgG or IgA paraprotein without biopsy features in 2b
-

**Table 8.** Cerebrospinal fluid (CSF) examination and nerve biopsy.

- 
- (1) CSF examination is most likely to be helpful in the following situations:
- (a) In patients with borderline demyelinating or axonal electrophysiology or atypical phenotype, where the presence of raised CSF protein would help suggest that the neuropathy is immune mediated
  - (b) The presence of malignant cells would confirm lymphoproliferative infiltration
- (2) Nerve biopsy (usually sural nerve) is most likely to be helpful when the following conditions are being considered:
- (a) Amyloidosis
  - (b) Vasculitis (e.g., due to cryoglobulinemia)
  - (c) Malignant lymphoproliferative infiltration of nerves, or
  - (d) Immunoglobulin M paraproteinemic demyelinating neuropathy (IgM PDN) with negative anti-myelin-associated glycoprotein antibodies, or IgG or IgA PDN with a chronic progressive course, where the discovery of widely spaced myelin on electron microscopy or deposits of immunoglobulin and/or complement bound to myelin would support a causal relationship between paraprotein and neuropathy
- However, clinical decisions on treatment are often made without a biopsy
- 

neuropathy (axonal and demyelinating) associated with all classes of MGUS, PE was significantly effective overall and in subgroups with IgG and IgA, but not in the 21 patients with IgM MGUS (*Dyck et al., 1991*) (class II). In this study, anti-MAG reactivity was not examined.

#### Corticosteroids

In a review of uncontrolled studies or case reports (*Nobile-Orazio et al., 2000*), approximately half of the patients responded to corticosteroids given in association with other therapies, but corticosteroids were seldom effective when used alone (class IV).

#### High-dose IVIg

IVIg was effective in two of 11 patients in a randomized double-blind placebo-controlled trial (*Dalakas et al., 1996*) (class II). A multicentre double-blind crossover trial of 22 patients with PDN with IgM MGUS, half of whom had anti-MAG IgM, showed significant improvement at 4 weeks with IVIg compared with placebo (*Comi et al., 2002*) (class II). The short duration of follow up leaves it unclear whether this was clinically useful. In an open study, 20 participants were randomized to IVIg or interferon- $\alpha$ , and only one of 10 treated with IVIg improved (*Mariette et al., 1997*) (class II).

#### Interferon- $\alpha$

In the open comparative trial against IVIg, eight of 10 patients with PDN and anti-MAG IgM improved with interferon- $\alpha$  (*Mariette et al., 1997*), but the improvement was restricted to sensory symptoms (class II). These results were not confirmed by the same authors in a randomized placebo-controlled study on 24 patients with PDN and anti-MAG IgM (*Mariette et al., 2000*) (class II).

#### Immunosuppressive therapies

In a review of uncontrolled studies or case reports (*Nobile-Orazio et al., 2000; Lunn and Nobile-Orazio, 2003*), chlorambucil was effective in one-third of

patients when used alone and in a slightly higher proportion in combination with other therapies (class IV).

Cyclophosphamide was rarely effective when used alone but was effective in 40–100% of patients in two open trials using cyclic high-dose oral or intravenous cyclophosphamide together with corticosteroids (*Notermans et al., 1996*) or PE (*Blume et al., 1995*) (class IV).

There are recent anecdotal reports on the efficacy of fludarabine (*Sherman et al., 1994; Wilson et al., 1999*), cladribine (*Ghosh et al., 2002*), and high-dose chemotherapy followed by autologous bone marrow transplantation (*Rudnicki et al., 1998*) in IgM PDN. These studies were limited to very small numbers and need to be confirmed in a larger series.

#### Rituximab

The humanized monoclonal antibody (Rituximab) against the CD20 antigen was tested in several recent open pilot trials. In an open prospective study, over 80% of 21 patients with neuropathy with IgM antibodies to neural antigens (including seven with PDN and anti-MAG IgM) improved in strength after 1 and 2 years, compared with none of 13 untreated patients (*Pestronk et al., 2003*) (class III). The average improvement in strength was 13% at 1 year and 23% at 2 years. However, it was not reported how many patients with anti-MAG antibodies improved or whether Rituximab improved the sensory ataxia, the most frequently disabling feature. No response to Rituximab was observed in two patients, including one with an IgM monoclonal gammopathy-associated chronic motor neuropathy with anti-ganglioside IgM antibodies (*Rojas-Garcia et al., 2003*). Six of nine patients with chronic polyneuropathy with IgM monoclonal gammopathy and anti-MAG IgM treated with Rituximab in an open phase II study had detectable improvement (defined as  $\geq 2$  points improvement in the neuropathy impairment score), two remained stable, and one worsened (*Renaud et al., 2003*). However, only two patients had clinically useful

improvement ( $\geq 10$  points), and four had marginal improvement (5 or less) (class IV).

#### Good practice points for treatment of IgM PDN

- 1 In patients without significant disability, consideration should be given to withholding immunosuppressive or immunomodulatory treatment, providing symptomatic treatment for tremor and paresthesiae, and giving reassurance that symptoms are unlikely to worsen significantly for several years.
- 2 In patients with significant disability or rapid worsening, IVIg or PE should be considered as initial treatment, although their efficacy is unproven.
- 3 In patients with moderate or severe disability, immunosuppressive treatment should be considered, although its long-term efficacy remains unproven. Preliminary reports suggest that Rituximab may be a promising therapy.
- 4 More research is needed.

#### IgG and IgA PDN

In a review of uncontrolled studies on a small series of patients (Nobile-Orazio *et al.*, 2002), 80% of those with CIDP-like neuropathy responded to the same immunotherapies used for CIDP (corticosteroids, PE, and IVIg) as compared with 20% of those with axonal neuropathy (Nobile-Orazio *et al.*, 2002) (class IV). The only randomized controlled trials, on 39 patients with neuropathy associated with MGUS including 18 with IgG or IgA MGUS and 21 with IgM (Dyck *et al.*, 1991), showed PE was efficacious compared with sham exchange in patients with IgG or IgA MGUS only (class II). No distinction between demyelinating and axonal forms of neuropathy was made in terms of response to therapy.

Good practice point for treatment of IgG and IgA PDN

In patients with a CIDP-like neuropathy, the detection of IgG or IgA MGUS does not justify a different therapeutic approach from CIDP without a paraprotein.

#### POEMS

There are no controlled trials on the treatment of neuropathy in POEMS. Patients with a solitary plasmacytoma may benefit from local radiation or surgical excision. In a recent retrospective study on 99 patients with POEMS (including a review of previous studies) (Dispenzieri *et al.*, 2003), 74% of patients had some response to therapy (class IV). Local radiation, performed only in patients with a localized or dominant plasmacytoma, was effective in 58% of 70 patients (54% improved and 4% stabilized) (class IV). A combination of melphalan and corticosteroids was effective in 56% of 48 patients (44% improved and 12% stabilized),

whereas corticosteroids alone were effective in 22% of 41 patients (class IV). PE, azathioprine, and cyclosporine were only effective when used in combination with corticosteroids. There is no evidence that PE, IVIg, or other immunosuppressive agents are effective when used alone. Tamoxifen, interferon- $\alpha$ , alkylating agents, and *trans*-retinoic acid have been used, but the evidence is insufficient. Autologous peripheral blood stem cell transplantation induced neurological improvement or stabilization in 14 of 16 patients but has significant morbidity (Dispenzieri *et al.*, 2004).

#### Good practice points for treatment of POEMS

- 1 Patients should be managed in consultation with a hemato-oncologist.
- 2 Local radiation or surgery should be considered as the initial treatment for isolated plasmacytoma.
- 3 Melphalan (with or without corticosteroids) should be considered for patients with multiple or no detectable bone lesions.

#### Other syndromes

In the neuropathy associated with multiple myeloma, there are no controlled trials and little evidence of response to any treatment in anecdotal reports. There are no controlled treatment trials in the neuropathy associated with Waldenström's macroglobulinemia.

#### Conflicts of Interest

The following authors have reported conflicts of interest as follows: R. Hughes, personal none, departmental research grants or honoraria from Bayer, Biogen-Idec, Schering-LFB, and Kedrion; D. Cornblath, personal honoraria from Aventis Behring and Baxter; C. Koski, personal honoraria from American Red Cross, Baxter, Bayer, and ZLB-Behring; J. M. Léger, personal none, departmental research grants or honoraria from Biogen-Idec, Baxter, Laboratoire Français du Biofractionnement (LFB), and Octapharma; E. Nobile-Orazio, personal honoraria from Kedrion, Grifols, Baxter, and LFB (and he has been commissioned by Kedrion and Baxter to give expert opinions to the Italian Ministry of Health on the use of IVIg in dysimmune neuropathies); J. Pollard, personal none, departmental research grants from Biogen-Idec and Schering; P. van Doorn, personal none, departmental research grants or honoraria from Baxter and Bayer. The other authors have nothing to declare.

#### Acknowledgements

We thank Dr. Michael Lunn for his comments on the text.

## References

- Alper E, Gurel M, Evrensel T, Ozkocaman V, Akbunar T, Demiray M (2003). 99mTc-MIBI scintigraphy in untreated stage III multiple myeloma: comparison with X-ray skeletal survey and bone scintigraphy. *Nucl Med Commun* 24:537–542.
- Baldini L, Nobile-Orazio E, Guffanti A, Barbieri S, Carpo M, Cro L, Cesana B, Damilano I, Maiolo AT (1994). Peripheral neuropathy in IgM monoclonal gammopathy and Waldenström's macroglobulinemia: a frequent complication in elderly males with low MAG-reactive serum monoclonal component. *Am J Hematol* 45:25–31.
- Balleari E, Villa G, Garre S, Ghirlanda P, Agnese G, Carletto M, Clavio M, Ferrando F, Gobbi M, Mariani G, Ghio R (2001). Technetium-99m-sestamibi scintigraphy in multiple myeloma and related gammopathies: a useful tool for the identification and follow-up of myeloma bone disease. *Haematologica* 86:78–84.
- Blume G, Pestronk A, Goodnough LT (1995). Anti-MAG antibody-associated polyneuropathies: improvement following immunotherapy with monthly plasma exchange and IV cyclophosphamide. *Neurology* 45:1577–1580.
- Brainin M, Barnes M, Baron JC, Gilhus NE, Hughes R, Selmaj K, Waldemar G; Guideline Standards Subcommittee of the EFNS Scientific Committee (2004). Guidance for the preparation of neurological management guidelines by EFNS scientific task forces – revised recommendations 2004. *Eur J Neurol* 11:577–581.
- Capasso M, Torrieri F, Di Muzio A, De Angelis MV, Lugaresi A, Uncini A (2002). Can electrophysiology differentiate polyneuropathy with anti-MAG/SGPG antibodies from chronic inflammatory demyelinating polyneuropathy? *Clin Neurophysiol* 113:346–353.
- Cesana C, Klersy C, Barbarano L, Nosari AM, Crugnola M, Pungolino E, Gargantini L, Granata S, Valentini M, Morra E (2002). Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. *J Clin Oncol* 20:1625–1634.
- Chan JK, Fletcher CD, Hicklin GA, Rosai J (1990). Glomeruloid hemangioma. A distinctive cutaneous lesion of multicentric Castleman's disease associated with POEMS syndrome. *Am J Surg Pathol* 14:1036–1046.
- Chassande B, Leger JM, Younes-Chennoufi AB, Bengoufa D, Maisonobe T, Bouche P, Baumann N (1998). Peripheral neuropathy associated with IgM monoclonal gammopathy: correlations between M-protein antibody activity and clinical/electrophysiological features in 40 cases. *Muscle Nerve* 21:55–62.
- Comi G, Roveri L, Swan A, Willison H, Bojar M, Illa I, Karageorgiou C, Nobile-Orazio E, van den Bergh P, Swan T, Hughes R, Aubry J, Baumann N, Hadden R, Lunn M, Knapp M, Leger JM, Bouche P, Mazanec R, Meucci N, van der Meche F, Toyka K; Inflammatory Neuropathy Cause and Treatment Group (2002). A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. *J Neurol* 249:1370–1377.
- Dalakas MC, Quarles RH, Farrer RG, Dambrosia J, Soueidan S, Stein DP, Cudler E, Sekul EA, Otero C (1996). A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. *Ann Neurol* 40:792–795.
- Di Troia A, Carpo M, Meucci N, Pellegrino C, Allaria S, Gemignani F, Marbini A, Mantegazza R, Sciolla R, Manfredini E, Scarlato G, Nobile-Orazio E (1999). Clinical features and anti-neural reactivity in neuropathy associated with IgM monoclonal gammopathy of undetermined significance. *J Neurol Sci* 164:64–71.
- Diaz-Arrastia R, Younger DS, Hair L, Inghirami G, Hays AP, Knowles DM, Odel JG, Fetell MR, Lovelace RE, Rowland LP (1992). Neurolymphomatosis: a clinicopathologic syndrome re-emerges. *Neurology* 42:1136–1141.
- Dispenzieri A, Kyle RA, Lacy MQ, Rajkumar SV, Therneau TM, Larson DR, Greipp PR, Witzig TE, Basu R, Suarez GA, Fonseca R, Lust JA, Gertz MA (2003). POEMS syndrome: definitions and long-term outcome. *Blood* 101:2496–2506.
- Dispenzieri A, Moreno-Aspitia A, Suarez GA, Lacy MQ, Colon-Otero G, Tefferi A, Litzow MR, Roy V, Hogan WJ, Kyle RA, Gertz MA (2004). Peripheral blood stem cell transplantation in 16 patients with POEMS syndrome, and a review of the literature. *Blood* 104:3400–3407.
- Dyck PJ, Low PA, Windebank AJ, Jaradeh SS, Gosselin S, Bourque P, Smith BE, Kratz KM, Karnes JL, Evans BA, et al. (1991). Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. *N Engl J Med* 325:1482–1486.
- Ghosh A, Littlewood T, Donaghy M (2002). Cladribine in the treatment of IgM paraproteinemic polyneuropathy. *Neurology* 59:1290–1291.
- Gregersen H, Mellemkjaer L, Ibsen JS, Dahlerup JF, Thomassen L, Sorensen HT (2001). The impact of M-component type and immunoglobulin concentration on the risk of malignant transformation in patients with monoclonal gammopathy of undetermined significance. *Haematologica* 86:1172–1179.
- Hughes RAC, Bouche P, Cornblath DR, Evers E, Hadden RD, Hahn AF, Illa I, Koski CL, Léger JM, Nobile-Orazio E, Pollard JD, Sommer C, Van den Bergh P, van Doorn PA, van Schaik IN (2005). European Federation of Neurological Societies/Peripheral Nerve Society Guideline\* on management of chronic inflammatory demyelinating polyradiculoneuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. *J Peripher Nerv Syst* 10:220–228.
- International Myeloma Working Group (2003). Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. *Br J Haematol* 121:749–757.
- Kaku DA, England JD, Sumner AJ (1994). Distal accentuation of conduction slowing in polyneuropathy associated with antibodies to myelin-associated glycoprotein and sulphated glucuronyl paragloboside. *Brain* 117:941–947.
- Katz JS, Saperstein DS, Gronseth G, Amato AA, Barohn RJ (2000). Distal acquired demyelinating symmetric neuropathy. *Neurology* 54:615–620.
- Kelly JJ Jr (1983). The electrodiagnostic findings in peripheral neuropathy associated with monoclonal gammopathy. *Muscle Nerve* 6:504–509.
- Kelly JJ, Kyle RA, Miles JM, O'Brien PC, Dyck PJ (1981). The spectrum of peripheral neuropathy in myeloma. *Neurology* 31:24–31.
- Keren DF (1999). Procedures for the evaluation of monoclonal immunoglobulins. *Arch Pathol Lab Med* 123:126–132.
- Kyle RA, Treon SP, Alexanian R, Barlogie B, Bjorkholm M, Dhodapkar M, Lister TA, Merlini G, Morel P, Stone M, Branagan AR, Leblond V (2003). Prognostic markers and criteria to initiate therapy in Waldenström's macroglobulinemia:

- consensus panel recommendations from the Second International Workshop on Waldenström's Macroglobulinemia. *Semin Oncol* 30:116–120.
- Latov N (1995). Pathogenesis and therapy of neuropathies associated with monoclonal gammopathies. *Ann Neurol* 37: S32–S42.
- Ludwig H, Kumpan W, Sinzinger H (1982). Radiography and bone scintigraphy in multiple myeloma: a comparative analysis. *Br J Radiol* 55:173–181.
- Lunn MP, Nobile-Orazio E (2003). Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. *Cochrane Database Syst Rev* 1:CD002827.
- Magy L, Chassande B, Maisonobe T, Bouche P, Vallat JM, Leger JM (2003). Polyneuropathy associated with IgG/IgA monoclonal gammopathy: a clinical and electrophysiological study of 15 cases. *Eur J Neurol* 10:677–685.
- Maisonobe T, Chassande B, Verin M, Jouni M, Leger JM, Bouche P (1996). Chronic dysimmune demyelinating polyneuropathy: a clinical and electrophysiological study of 93 patients. *J Neurol Neurosurg Psychiatry* 61:36–42.
- Mariette X, Brouet JC, Chevret S, Leger JM, Clavelou P, Pouget J, Vallat JM, Vital C (2000). A randomised double blind trial versus placebo does not confirm the benefit of alpha-interferon in polyneuropathy associated with monoclonal IgM. *J Neurol Neurosurg Psychiatry* 69:279–280.
- Mariette X, Chastang C, Clavelou P, Louboutin JP, Leger JM, Brouet JC (1997). A randomised clinical trial comparing interferon-alpha and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM. The IgM-associated Polyneuropathy Study Group. *J Neurol Neurosurg Psychiatry* 63:28–34.
- Mehndiratta MM, Sen K, Tatke M, Bajaj BK (2004). IgA monoclonal gammopathy of undetermined significance with peripheral neuropathy. *J Neurol Sci* 221:99–104.
- Morra E, Cesana C, Klersy C, Barbarano L, Varettoni M, Cavanna L, Canesi B, Tresoldi E, Miquelisz S, Bernuzzi P, Nosari AM, Lazzarino M (2004). Clinical characteristics and factors predicting evolution of asymptomatic IgM monoclonal gammopathies and IgM-related disorders. *Leukemia* 18:1512–1517.
- Nobile-Orazio E, Casellato C, Di Troia A (2002). Neuropathies associated with IgG and IgA monoclonal gammopathy. *Rev Neurol (Paris)* 158:979–987.
- Nobile-Orazio E, Manfredini E, Carpo M, Meucci N, Monaco S, Ferrari S, Bonetti B, Cavaletti G, Gemignani F, Durelli L, Barbieri S, Allaria S, Sgarzi M, Scarlato G (1994). Frequency and clinical correlates of anti-neural IgM antibodies in neuropathy associated with IgM monoclonal gammopathy. *Ann Neurol* 36:416–424.
- Nobile-Orazio E, Meucci N, Baldini L, Di Troia A, Scarlato G (2000). Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies. *Brain* 123:710–717.
- Notermans NC, Franssen H, Eurelings M, Van der Graaf Y, Wokke JH (2000). Diagnostic criteria for demyelinating polyneuropathy associated with monoclonal gammopathy. *Muscle Nerve* 23:73–79.
- Notermans NC, Lokhorst HM, Franssen H, Van der Graaf Y, Teunissen LL, Jennekens FG, Van den Berg LH, Wokke JH (1996). Intermittent cyclophosphamide and prednisone treatment of polyneuropathy associated with monoclonal gammopathy of undetermined significance. *Neurology* 47:1227–1233.
- Oksenhendler E, Chevret S, Leger JM, Louboutin JP, Bussel A, Brouet JC (1995). Plasma exchange and chlorambucil in polyneuropathy associated with monoclonal IgM gammopathy. IgM-associated Polyneuropathy Study Group. *J Neurol Neurosurg Psychiatry* 59:243–247.
- Owen RG (2003). Developing diagnostic criteria in Waldenström's macroglobulinemia. *Semin Oncol* 30:196–200.
- Pestronk A, Florence J, Miller T, Choksi R, Al-Lozi MT, Levine TD (2003). Treatment of IgM antibody associated polyneuropathies using rituximab. *J Neurol Neurosurg Psychiatry* 74:485–489.
- Renaud S, Gregor M, Fuhr P, Lorenz D, Deuschl G, Gratwohl A, Steck AJ (2003). Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies. *Muscle Nerve* 27:611–615.
- Rojas-Garcia R, Gallardo E, de Andres I, de Luna N, Juarez C, Sanchez P, Illa I (2003). Chronic neuropathy with IgM anti-ganglioside antibodies: lack of long term response to rituximab. *Neurology* 61:1814–1816.
- Ropper AH, Gorson KC (1998). Neuropathies associated with paraproteinemia. *N Engl J Med* 338:1601–1607.
- Rudnicki SA, Harik SI, Dhodapkar M, Barlogie B, Eidelberg D (1998). Nervous system dysfunction in Waldenström's macroglobulinemia: response to treatment. *Neurology* 51:1210–1213.
- Sherman WH, Latov N, Lange DE, Hays R, Younger DS (1994). Fludarabine for IgM antibody-mediated neuropathies (Abstract). *Ann Neurol* 36:326–327.
- Simovic D, Gorson KC, Ropper AH (1998). Comparison of IgM-MGUS and IgG-MGUS polyneuropathy. *Acta Neurol Scand* 97:194–200.
- Sung JY, Kuwabara S, Ogawara K, Kanai K, Hattori T (2002). Patterns of nerve conduction abnormalities in POEMS syndrome. *Muscle Nerve* 26:189–193.
- Vallat JM, Tabaraud F, Sindou P, Preux PM, Vandenberghe A, Steck A (2000). Myelin widenings and MGUS-IgA: an immunoelectron microscopic study. *Ann Neurol* 47:808–811.
- Van den Berg L, Hays AP, Nobile-Orazio E, Kinsella LJ, Manfredini E, Corbo M, Rosoklija G, Younger DS, Lovelace RE, Trojaborg W, Lange DE, Goldstein S, Delfiner JS, Sadiq SA, Sherman WH, Latov N (1996). Anti-MAG and anti-SGPG antibodies in neuropathy. *Muscle Nerve* 19:637–643.
- Vital A, Lagueny A, Julien J, Ferrer X, Barat M, Hermsilla E, Rouanet-Larriviere M, Henry P, Bredin A, Louiset P, Herbelleau T, Boisseau C, Guiraud-Chaumeil B, Steck A, Vital C (2000). Chronic inflammatory demyelinating polyneuropathy associated with dysglobulinemia: a peripheral nerve biopsy study in 18 cases. *Acta Neuropathol (Berl)* 100:63–68.
- Vital C, Vital A, Bouillot S, Favereaux A, Lagueny A, Ferrer X, Brechenmacher C, Petry KG (2003). Uncompacted myelin lamellae in peripheral nerve biopsy. *Ultrastruct Pathol* 27:1–5.
- Vital C, Vital A, Bouillot-Eimer S, Brechenmacher C, Ferrer X, Lagueny A (2004). Amyloid neuropathy: a retrospective study of 35 peripheral nerve biopsies. *J Peripher Nerv Syst* 9:232–241.
- Vrethem M, Larsson B, von Schenck H, Ernerudh J (1993). Immunofixation superior to plasma agarose electrophoresis in detecting small M-components in patients with polyneuropathy. *J Neurol Sci* 120:93–98.
- Watanabe O, Maruyama I, Arimura K, Kitajima I, Arimura H, Hanatani M, Matsuo K, Arisato T, Osame M (1998). Overproduction of vascular endothelial growth factor/vascular permeability factor is causative in Crow-Fukase (POEMS) syndrome. *Muscle Nerve* 21:1390–1397.

Willison HJ, O’Leary CP, Veitch J, Blumhardt LD, Busby M, Donaghy M, Fuhr P, Ford H, Hahn A, Renaud S, Katifi HA, Ponsford S, Reuber M, Steck A, Sutton I, Schady W, Thomas PK, Thompson AJ, Vallat JM, Winer J (2001). The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies. *Brain* 124:1968–1977.

Wilson HC, Lunn MP, Schey S, Hughes RA (1999). Successful treatment of IgM paraproteinaemic neuropathy with fludarabine. *J Neurol Neurosurg Psychiatry* 66:575–580.

Yeung KB, Thomas PK, King RH, Waddy H, Will RG, Hughes RA, Gregson NA, Leibowitz S (1991). The clinical spectrum of peripheral neuropathies associated with benign monoclonal IgM, IgG and IgA paraproteinaemia. Comparative clinical, immunological and nerve biopsy findings. *J Neurol* 238:383–391.

of the Peripheral Nerve Society (PNS). Additional non-European members of the Task Force were appointed on the recommendation of the Board of Directors of the PNS. The Task Force adopted the methods and classification scheme of the EFNS (Appendix Tables 1 and 2). Where only class IV evidence existed, a consensus was expressed as a good practice point (*Brainin et al., 2004*). ‘The aim of an EFNS neurological management guideline is to provide evidence-based guidance for clinical neurologists, other health care professionals, and health care providers about important aspects of management of neurological disease. It provides the view of an expert task force appointed by the Scientific Committee of the EFNS. It represents a peer-reviewed statement of minimum desirable standards for the guidance of practice based on the best available evidence. It is not intended to have legally binding implications in individual cases’ (*Brainin et al., 2004*). This guideline is not intended to have implications regarding reimbursement.

## Appendix: Guidelines

### Aim of guidelines

This guideline has been produced by the Task Force members of the European Federation of Neurological Societies (EFNS) who are also members

### Appendix Table 1. Evidence classification scheme for a therapeutic intervention.

Class I: An adequately powered prospective, randomized, controlled clinical trial with masked outcome assessment in a representative population or an adequately powered systematic review of prospective randomized controlled clinical trials with masked outcome assessment in representative populations. The following are required:

- (a) randomization concealment;
- (b) primary outcome(s) is/are clearly defined;
- (c) exclusion/inclusion criteria are clearly defined;
- (d) adequate accounting for dropouts and crossovers with numbers sufficiently low to have minimal potential for bias;
- (e) relevant baseline characteristics are presented and substantially equivalent among treatment groups, or there is appropriate statistical adjustment for differences.

Class II: Prospective matched-group cohort study in a representative population with masked outcome assessment that meets (a–e) above or a randomized, controlled trial in a representative population that lacks one criterion (a–e)

Class III: All other controlled trials (including well-defined natural history controls or patients serving as own controls) in a representative population, where outcome assessment is independent of patient treatment

Class IV: Evidence from uncontrolled studies, case series, case reports, or expert opinion

#### Rating of recommendations

Level A rating (established as effective, ineffective, or harmful) requires at least one convincing class I study or at least two consistent, convincing class II studies

Level B rating (probably effective, ineffective, or harmful) requires at least one convincing class II study or overwhelming class III evidence

Level C rating (possibly effective, ineffective, or harmful) rating requires at least two convincing class III studies

### Appendix Table 2. Evidence classification scheme for a diagnostic measure.

Class I: A prospective study in a broad spectrum of persons with the suspected condition, using a ‘gold standard’ for case definition, where the test is applied in a blinded evaluation, and enabling the assessment of appropriate tests of diagnostic accuracy

Class II: A prospective study of a narrow spectrum of persons with the suspected condition, or a well-designed retrospective study of a broad spectrum of persons with an established condition (by gold standard) compared with a broad spectrum of controls, where test is applied in a blinded evaluation, and enabling the assessment of appropriate tests of diagnostic accuracy

Class III: Evidence provided by a retrospective study where either persons with the established condition or controls are of a narrow spectrum, and where test is applied in a blinded evaluation

Class IV: Any design where test is not applied in a blinded evaluation, or evidence provided by expert opinion alone or in descriptive case series (without controls)

#### Rating of recommendations

Level A rating (established as useful/predictive or not useful/predictive) requires at least one convincing class I study or at least two consistent, convincing class II studies

Level B rating (established as probably useful/predictive or not useful/predictive) requires at least one convincing class II study or overwhelming class III evidence

Level C rating (established as possibly useful/predictive or not useful/predictive) requires at least two convincing class III studies